Arnhold LLC raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 11.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 772,262 shares of the biopharmaceutical company's stock after acquiring an additional 78,780 shares during the period. Pfizer accounts for approximately 1.7% of Arnhold LLC's portfolio, making the stock its 17th largest position. Arnhold LLC's holdings in Pfizer were worth $18,720,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the first quarter valued at about $27,000. North Capital Inc. purchased a new position in Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd purchased a new position in Pfizer during the first quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new position in Pfizer during the second quarter worth about $29,000. Finally, Horizon Financial Services LLC purchased a new position in Pfizer in the first quarter valued at about $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Stock Up 1.2%
Shares of NYSE PFE opened at $24.52 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.36. The firm's 50 day moving average price is $24.89 and its 200 day moving average price is $24.12. The firm has a market cap of $139.38 billion, a P/E ratio of 13.04, a price-to-earnings-growth ratio of 0.80 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.
Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the business earned $0.60 earnings per share. Pfizer's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.
Analysts Set New Price Targets
PFE has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. UBS Group reaffirmed a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley lowered their price target on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $28.13.
Read Our Latest Stock Analysis on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.